Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Clinicoeconomics and Outcomes Research : CEOR|May 30, 2023
Cost-Effectiveness of Aripiprazole Tablets with Sensor versus Oral Atypical Antipsychotics for the Treatment of Schizophrenia Using a Patient-Level Microsimulation Modeling ApproachAvijeet S Chopra, Dusica Hadzi Boskovic, Amit Kulkarni, et al.
Cancer Biology & Therapy|February 5, 2013
Identification of novel compounds that enhance colon cancer cell sensitivity to inflammatory apoptotic ligandsAvijeet S Chopra, Anton Kuratnik, Eric W Scocchera, et al.
Advances in Therapy|June 12, 2026
Assessment of the MFSAF v4.0 and PROMIS Fatigue 7a to Measure Outcomes in Myelofibrosis: Validation from a Non-interventional Mixed Methods StudyAmy Howerter, Helen Doll, Angela Stroupe, et al.
Muscle & Nerve|December 7, 2017
Estimating the global prevalence of transthyretin familial amyloid polyneuropathyHartmut H Schmidt, Márcia Waddington-Cruz, Marc F Botteman, et al.
Pharmacological Research|November 26, 2021
The current use and evolving landscape of nutraceuticalsAvijeet S Chopra, Ronan Lordan, Olaf K Horbańczuk, et al.
Blood Advances|December 27, 2024
Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER studyVikas Gupta, Ciprian Tomuleasa, Gilberto Israel Barranco Lampón, et al.
Hematological Oncology|March 18, 2026
Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE)Francesco Passamonti, James M Foran, Anand Tandra, et al.
Blood|June 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosisNaveen Pemmaraju, Adam J Mead, Tim C P Somervaille, et al.
Pageof 1